RYBREVANT and RYBREVANT FASPRO Coverage for EGFR-Mutated Non-Small Cell Lung Cancer
Customize your policy alerts
Sign up for all goldcoasthealthplan policy alerts
Know when goldcoasthealthplan releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization and Part B coverage criteria for physician-administered intravenous RYBREVANT and subcutaneous RYBREVANT FASPRO in adults with recurrent, advanced, or metastatic NSCLC and qualifying EGFR mutations.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.